Natco Announces Generic VELPANAT For Nepal Market

Natco has announced the launch of of generic VELPANAT in Nepal. Natco said that its launch of the generic a–Sofosbuvir 400 mg/Velpatasvir 100 mg fixed dose combination–was the first in Nepal. The drug is the generic version of Gilead Sciences’ brand name Epclusa drug. Epclusa is used to treat adults suffering from genotype 1-6 chronic hepatitis C virus. Natco has signed a non-exclusive licensing agreement with Gilead in order to manufacture and sell generic chronic hepatitis C drugs in 101 developing nations.

Read the source article at The Business Standard